食管癌在恶性肿瘤中位居第4位,其发病率、病死率极高。食管癌早期发病极为隐匿,症状显现时已发展至中晚期,该阶段患者已失去手术治疗机会,同步放化疗是主要治疗手段,可提升患者生存率,但易增加不良反应~([1])。以顺铂为基础联合药物化疗是食管癌传统化疗方案,但顺铂诱发的消化道不良反应高,对食管癌患者化疗造成极大痛苦而中断治疗,明显降低 Esophageal cancer is the fourth most common malignant tumor with a very high morbidity and mortality. Early onset of esophageal cancer is extremely occult, the symptoms have developed to the advanced stage, the patient has lost the opportunity for surgical treatment, concurrent chemoradiation is the main treatment, can improve patient survival, but easy to increase adverse reactions ~ ([1]) . Cisplatin-based combination chemotherapy is a traditional chemotherapy regimen of esophageal cancer, but cisplatin-induced gastrointestinal adverse reactions, chemotherapy in patients with esophageal cancer caused great pain and interruption of treatment, significantly reduced